In: In vivo CAR-T
What this is
- How it works
- Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo BCMA CAR-T, lentiviral
- How it’s given
- “ESO-T01 injection is the third-generation self-inactivating lentiviral vector targeting T cells in vivo, which carries a single VHH-directed BCMA-targeted CAR.”In the company’s words, NCT06791681 on ClinicalTrials.gov
- Tested for
- Relapsed/ Refractory Multiple Myeloma
- Main trialEarly Phase 1
- “This is a single center, single arm, open-label, dose-escalation clinical study to observe the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics of ESO-T01 injection for treating patients with relapsed/refractory multiple myeloma.”In the company’s words, NCT06791681 on ClinicalTrials.gov
Coming up1
- 30 Nov 2027Early Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Early Phase 1Recruiting | 30 Nov 2027 | A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma | |
| Early Phase 1Suspended | 1 Nov 2027 | A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026